Dart NeuroScience, LLC

United States of America

Back to Profile

1-48 of 48 for Dart NeuroScience, LLC Sort by
Query
Patent
Aggregations Reset Report
Jurisdiction
        United States 34
        World 10
        Canada 4
Date
New (last 4 weeks) 2
2025 May (MTD) 2
2025 April 1
2025 March 2
2025 (YTD) 5
See more
IPC Class
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or 16
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings 14
C07D 487/04 - Ortho-condensed systems 12
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia 9
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links 8
See more
Status
Pending 10
Registered / In Force 38
Found results for  patents

1.

SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS

      
Application Number 18737420
Status Pending
Filing Date 2024-06-07
First Publication Date 2025-05-08
Owner Dart NeuroScience, LLC (USA)
Inventor
  • Bookser, Brett
  • Botrous, Iriny
  • Burns, Aaron
  • Chung, Demichael
  • Dyck, Brian
  • Kleinke, Andrew
  • Kumar, Dange Vijay
  • Mccarrick, Margaret
  • Raffaele, Nicholas
  • Tran, Joe
  • Weinhouse, Michael

Abstract

Substituted furanopyrimidine chemical entities of Formula (I): Substituted furanopyrimidine chemical entities of Formula (I): Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

IPC Classes  ?

  • C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

2.

SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

      
Application Number 18677491
Status Pending
Filing Date 2024-05-29
First Publication Date 2025-05-01
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Gomez, Laurent
  • Vernier, William Francois

Abstract

A chemical entity of Formula (I): A chemical entity of Formula (I): A chemical entity of Formula (I): wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

3.

SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS

      
Application Number 18661369
Status Pending
Filing Date 2024-05-10
First Publication Date 2025-04-17
Owner Dart Neuroscience, LLC (USA)
Inventor
  • Bollu, Venkataiah
  • Breitenbucher, James
  • Kaplan, Alan
  • Lemus, Robert
  • Lindstrom, Andrew
  • Vickers, Troy
  • Weinhouse, Michael
  • Wilson, Mark E.
  • Zapf, James

Abstract

The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders, including inflammatory and renal disorders.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 51/04 - Organic compounds
  • C07D 213/64 - One oxygen atom attached in position 2 or 6
  • C07D 213/73 - Unsubstituted amino or imino radicals
  • C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
  • C07D 213/81 - AmidesImides
  • C07D 239/34 - One oxygen atom
  • C07D 241/18 - Oxygen or sulfur atoms
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

4.

SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS

      
Application Number 18613695
Status Pending
Filing Date 2024-03-22
First Publication Date 2025-03-20
Owner Dart Neuroscience, LLC (USA)
Inventor
  • Breitenbucher, James
  • Freestone, Graeme
  • Gomez, Laurent
  • Lemus, Robert
  • Ly, Kiev
  • Mccarrick, Margaret
  • Vernier, William
  • Vickers, Troy

Abstract

The invention provides a chemical entity of Formula (I): The invention provides a chemical entity of Formula (I): The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

5.

SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS

      
Application Number 18615722
Status Pending
Filing Date 2024-03-25
First Publication Date 2025-03-20
Owner Dart NeuroScience, LLC (USA)
Inventor
  • Thompson, Jillian Basinger
  • Bookser, Brett C.
  • Burley, Scott
  • Garcia-Reynaga, Pablo
  • Hudson, Andrew
  • Peters, Marco
  • Pratt, Benjamin
  • Thompson, Aaron
  • Tran, Joe
  • Valdez, Lino

Abstract

Substituted cyclohexyl chemical entities of Formula (I): Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

IPC Classes  ?

  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07C 211/40 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
  • C07C 237/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
  • C07C 255/46 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
  • C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
  • C07D 207/273 - 2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
  • C07D 211/58 - Nitrogen atoms attached in position 4
  • C07D 211/76 - Oxygen atoms attached in position 2 or 6
  • C07D 211/96 - Sulfur atom
  • C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
  • C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

6.

SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS

      
Application Number 18210382
Status Pending
Filing Date 2023-06-15
First Publication Date 2024-06-20
Owner Dart NeuroScience, LLC (USA)
Inventor
  • Santora, Vincent John
  • Chen, Mi
  • Chung, Demichael

Abstract

Substituted benzoxazole and benzofuran chemical entities of Formula (I): Substituted benzoxazole and benzofuran chemical entities of Formula (I): Substituted benzoxazole and benzofuran chemical entities of Formula (I): wherein, V, W, X, Y, Z, and m have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; and the treatment of one or more disorders, including neurological, cognitive, immunological, and inflammatory disorders, as well as other conditions and diseases involving PDE7 or cyclic nucleotide signaling.

IPC Classes  ?

  • C07D 498/10 - Spiro-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

7.

Substituted furanopyrimidine compounds as PDE1 inhibitors

      
Application Number 17902730
Grant Number 12006325
Status In Force
Filing Date 2022-09-02
First Publication Date 2023-09-21
Grant Date 2024-06-11
Owner Dart NeuroScience, LLC (USA)
Inventor
  • Bookser, Brett
  • Botrous, Iriny
  • Burns, Aaron
  • Chung, Demichael
  • Dyck, Brian
  • Kleinke, Andrew
  • Kumar, Dange Vijay
  • Mccarrick, Margaret
  • Raffaele, Nicholas
  • Tran, Joe
  • Weinhouse, Michael

Abstract

Substituted furanopyrimidine chemical entities of Formula (I): a has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

IPC Classes  ?

  • C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

8.

Substituted cyclohexyl compounds as NOP inhibitors

      
Application Number 17841570
Grant Number 11945808
Status In Force
Filing Date 2022-06-15
First Publication Date 2023-05-11
Grant Date 2024-04-02
Owner Dart Neuroscience, LLC (USA)
Inventor
  • Thompson, Jillian Basinger
  • Bookser, Brett C.
  • Burley, Scott
  • Garcia-Reynaga, Pablo
  • Hudson, Andrew
  • Peters, Marco
  • Pratt, Benjamin
  • Thompson, Aaron
  • Tran, Joe
  • Valdez, Lino

Abstract

Substituted cyclohexyl chemical entities of Formula (I): b have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

IPC Classes  ?

  • C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07C 211/40 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
  • C07C 237/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
  • C07C 255/46 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
  • C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
  • C07D 207/273 - 2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
  • C07D 211/58 - Nitrogen atoms attached in position 4
  • C07D 211/76 - Oxygen atoms attached in position 2 or 6
  • C07D 211/96 - Sulfur atom
  • C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

9.

Substituted furanopyrimidine compounds as PDE1 inhibitors

      
Application Number 16766258
Grant Number 11434247
Status In Force
Filing Date 2020-05-21
First Publication Date 2022-09-06
Grant Date 2022-09-06
Owner Dart Neuroscience LLC (USA)
Inventor
  • Bookser, Brett
  • Botrous, Iriny
  • Burns, Aaron
  • Chung, Demichael
  • Dyck, Brian
  • Kleinke, Andrew
  • Kumar, Dange Vijay
  • Mccarrick, Margaret
  • Raffaele, Nicholas
  • Tran, Joe
  • Weinhouse, Michael

Abstract

a has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

IPC Classes  ?

  • C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

10.

Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors

      
Application Number 16629922
Grant Number 11685745
Status In Force
Filing Date 2018-07-11
First Publication Date 2022-08-25
Grant Date 2023-06-27
Owner Dart Neuroscience, LLC (USA)
Inventor
  • Santora, Vincent John
  • Chen, Mi
  • Chung, Demichael

Abstract

Substituted benzoxazole and benzofuran chemical entities of Formula (I): wherein, V, W, X, Y, Z, and m have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; and the treatment of one or more disorders, including neurological, cognitive, immunological, and inflammatory disorders, as well as other conditions and diseases involving PDE7 or cyclic nucleotide signaling.

IPC Classes  ?

  • C07D 498/10 - Spiro-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

11.

Substituted cyclohexyl compounds as NOP inhibiiors

      
Application Number 16976363
Grant Number 11365191
Status In Force
Filing Date 2019-02-26
First Publication Date 2021-11-04
Grant Date 2022-06-21
Owner Dart NeuroScience, LLC (USA)
Inventor
  • Thompson, Jillian Basinger
  • Bookser, Brett C.
  • Burley, Scott
  • Garcia-Reynaga, Pablo
  • Hudson, Andrew
  • Peters, Marco
  • Pratt, Benjamin
  • Thompson, Aaron
  • Tran, Joe
  • Valdez, Lino

Abstract

b have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

IPC Classes  ?

  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
  • C07C 255/46 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
  • C07D 211/76 - Oxygen atoms attached in position 2 or 6
  • C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
  • C07D 207/273 - 2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
  • C07C 211/40 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
  • C07D 211/58 - Nitrogen atoms attached in position 4
  • C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07C 237/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
  • C07D 211/96 - Sulfur atom
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

12.

Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors

      
Application Number 17232015
Grant Number 11999738
Status In Force
Filing Date 2021-04-15
First Publication Date 2021-11-04
Grant Date 2024-06-04
Owner Dart NeuroScience, LLC (USA)
Inventor
  • Gomez, Laurent
  • Vernier, William Francois

Abstract

A chemical entity of Formula (I): wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

13.

Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors

      
Application Number 16473864
Grant Number 10981916
Status In Force
Filing Date 2017-12-22
First Publication Date 2020-05-14
Grant Date 2021-04-20
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Gomez, Laurent
  • Vernier, William Francois

Abstract

A chemical entity of Formula (I), wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities, methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques, radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function, enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatoiogical, inflammatory, and pain disorders.

IPC Classes  ?

  • A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
  • A61K 31/52 - Purines, e.g. adenine
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
  • C07D 487/04 - Ortho-condensed systems
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

14.

Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors

      
Application Number 16694869
Grant Number 11186582
Status In Force
Filing Date 2019-11-25
First Publication Date 2020-03-26
Grant Date 2021-11-30
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Breitenbucher, James
  • Freestone, Graeme
  • Gomez, Laurent
  • Lemus, Robert
  • Ly, Kiev
  • Mccarrick, Margaret
  • Vernier, William
  • Vickers, Troy

Abstract

The invention provides a chemical entity of Formula (I): 2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61P 25/24 - Antidepressants
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/22 - Anxiolytics
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

15.

Substituted pyridine and pyrazine compounds as PDE4 inhibitors

      
Application Number 16424366
Grant Number 11279691
Status In Force
Filing Date 2019-05-28
First Publication Date 2020-01-23
Grant Date 2022-03-22
Owner Dart Neuroscience LLC (USA)
Inventor
  • Bollu, Venkataiah
  • Breitenbucher, James
  • Kaplan, Alan
  • Lemus, Robert
  • Lindstrom, Andrew
  • Vickers, Troy
  • Weinhouse, Michael
  • Wilson, Mark E.
  • Zapf, James

Abstract

The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

IPC Classes  ?

  • A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61M 36/14 - Radioactive dressings
  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 213/73 - Unsubstituted amino or imino radicals
  • C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
  • C07D 213/81 - AmidesImides
  • C07D 213/64 - One oxygen atom attached in position 2 or 6
  • C07D 241/18 - Oxygen or sulfur atoms
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 51/04 - Organic compounds
  • C07D 239/34 - One oxygen atom

16.

SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS

      
Application Number US2019019650
Publication Number 2019/168866
Status In Force
Filing Date 2019-02-26
Publication Date 2019-09-06
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Basinger, Thompson, Jillian
  • Bookser, Brett
  • Burley, Scott
  • Garcia-Reynaga, Pablo
  • Hudson, Andrew
  • Peters, Marco
  • Pratt, Benjamin
  • Thompson, Aaron
  • Tran, Joe
  • Valdez, Lino

Abstract

Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

IPC Classes  ?

  • C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • A61K 31/121 - Ketones acyclic
  • A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
  • A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
  • C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
  • C07C 211/35 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
  • C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
  • C07C 229/46 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
  • C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
  • C07D 211/72 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D 213/24 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D 307/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

17.

SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS

      
Document Number 03131420
Status Pending
Filing Date 2019-02-26
Open to Public Date 2019-09-06
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Basinger Thompson, Jillian
  • Bookser, Brett
  • Burley, Scott
  • Garcia-Reynaga, Pablo
  • Hudson, Andrew
  • Peters, Marco
  • Pratt, Benjamin
  • Thompson, Aaron
  • Tran, Joe
  • Valdez, Lino

Abstract

Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

IPC Classes  ?

  • A61K 31/121 - Ketones acyclic
  • A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
  • A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
  • C07C 211/35 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
  • C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
  • C07C 229/46 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
  • C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
  • C07D 211/72 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D 213/24 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D 307/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D 309/14 - Nitrogen atoms not forming part of a nitro radical

18.

SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS

      
Application Number US2018062493
Publication Number 2019/104285
Status In Force
Filing Date 2018-11-26
Publication Date 2019-05-31
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Bookser, Brett
  • Botrous, Iriny
  • Burns, Aaron
  • Chung, Demichael
  • Dyck, Brian
  • Kleinke, Andrew
  • Kumar, Dange, Vijay
  • Mccarrick, Margaret
  • Raffaele, Nicholas
  • Tran, Joe
  • Weinhouse, Michael

Abstract

Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

IPC Classes  ?

  • C07D 491/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61P 25/16 - Anti-Parkinson drugs
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

19.

SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS

      
Document Number 03120971
Status Pending
Filing Date 2018-11-26
Open to Public Date 2019-05-31
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Bookser, Brett
  • Botrous, Iriny
  • Burns, Aaron
  • Chung, Demichael
  • Dyck, Brian
  • Kleinke, Andrew
  • Kumar, Dange Vijay
  • Mccarrick, Margaret
  • Raffaele, Nicholas
  • Tran, Joe
  • Weinhouse, Michael

Abstract

Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 25/16 - Anti-Parkinson drugs
  • C07D 491/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

20.

Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones

      
Application Number 16164726
Grant Number 10376514
Status In Force
Filing Date 2018-10-18
First Publication Date 2019-02-14
Grant Date 2019-08-13
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Branstetter, Bryan
  • Breitenbucher, James
  • Dyck, Brian
  • Gomez, Laurent
  • Hudson, Andrew Richard
  • Marrone, Tami Jo
  • Peters, Marco
  • Vickers, Troy
  • Weinhouse, Michael I.

Abstract

Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

IPC Classes  ?

  • C07D 495/14 - Ortho-condensed systems
  • C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
  • C07D 471/14 - Ortho-condensed systems
  • C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
  • C07D 487/14 - Ortho-condensed systems
  • C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
  • C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • C07D 498/08 - Bridged systems
  • C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 495/12 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 9/00 - Drugs for disorders of the cardiovascular system

21.

SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS

      
Application Number US2018041565
Publication Number 2019/014305
Status In Force
Filing Date 2018-07-11
Publication Date 2019-01-17
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Santora, Vincent, John
  • Chen, Mi
  • Chung, Demichael

Abstract

mm have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; and the treatment of one or more disorders, including neurological, cognitive, immunological, and inflammatory disorders, as well as other conditions and diseases involving PDE7 or cyclic nucleotide signaling.

IPC Classes  ?

  • C07D 491/04 - Ortho-condensed systems
  • C07D 498/04 - Ortho-condensed systems
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

22.

SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS

      
Document Number 03069432
Status Pending
Filing Date 2018-07-11
Open to Public Date 2019-01-17
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Santora, Vincent John
  • Chen, Mi
  • Chung, Demichael

Abstract

Substituted benzoxazole and benzofuran chemical entities of Formula (I): wherein, V, W, X, Y, Z, and m have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; and the treatment of one or more disorders, including neurological, cognitive, immunological, and inflammatory disorders, as well as other conditions and diseases involving PDE7 or cyclic nucleotide signaling.

IPC Classes  ?

  • A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61P 25/00 - Drugs for disorders of the nervous system
  • C07D 491/04 - Ortho-condensed systems
  • C07D 498/04 - Ortho-condensed systems

23.

Compounds for therapeutic use

      
Application Number 15972966
Grant Number 10738018
Status In Force
Filing Date 2018-05-07
First Publication Date 2018-09-06
Grant Date 2020-08-11
Owner Dart Neuroscience, LLC (USA)
Inventor
  • Gomez, Laurent
  • Massari, Mark Eben

Abstract

Chemical entities of Formula (I): 1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

IPC Classes  ?

  • C07D 265/16 - 1,3-OxazinesHydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07F 11/00 - Compounds containing elements of Groups 6 or 16 of the Periodic Table
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

24.

SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

      
Application Number US2017068229
Publication Number 2018/125810
Status In Force
Filing Date 2017-12-22
Publication Date 2018-07-05
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Gomez, Laurent
  • Vernier, William, Francois

Abstract

A chemical entity of Formula (I), wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities, methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques, radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function, enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatoiogical, inflammatory, and pain disorders.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/24 - Antidepressants
  • A61P 25/22 - Anxiolytics

25.

SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

      
Document Number 03047408
Status Pending
Filing Date 2017-12-22
Open to Public Date 2018-07-05
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Gomez, Laurent
  • Vernier, William Francois

Abstract

A chemical entity of Formula (I), wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities, methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques, radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function, enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatoiogical, inflammatory, and pain disorders.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • C07D 487/04 - Ortho-condensed systems

26.

Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors

      
Application Number 15905672
Grant Number 10501465
Status In Force
Filing Date 2018-02-26
First Publication Date 2018-06-28
Grant Date 2019-12-10
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Breitenbucher, James
  • Freestone, Graeme
  • Gomez, Laurent
  • Lemus, Robert
  • Ly, Kiev
  • Mccarrick, Margaret
  • Vernier, William
  • Vickers, Troy

Abstract

The invention provides a chemical entity of Formula (I): 2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 487/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants

27.

HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS

      
Application Number US2017049129
Publication Number 2018/044896
Status In Force
Filing Date 2017-08-29
Publication Date 2018-03-08
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Gomez, Laurent
  • Massari, Mark, Eben

Abstract

Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

IPC Classes  ?

  • C07D 265/14 - 1,3-OxazinesHydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
  • A61P 25/24 - Antidepressants

28.

Compounds for therapeutic use

      
Application Number 15253645
Grant Number 09963435
Status In Force
Filing Date 2016-08-31
First Publication Date 2018-03-01
Grant Date 2018-05-08
Owner Dart NeuroScience, LLC (USA)
Inventor
  • Gomez, Laurent
  • Massari, Mark Eben

Abstract

Chemical entities of Formula (I): 1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

IPC Classes  ?

  • C07D 265/16 - 1,3-OxazinesHydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07F 11/00 - Compounds containing elements of Groups 6 or 16 of the Periodic Table

29.

Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds

      
Application Number 15354804
Grant Number 10092575
Status In Force
Filing Date 2016-11-17
First Publication Date 2017-07-27
Grant Date 2018-10-09
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Branstetter, Bryan
  • Breitenbucher, James
  • Dyck, Brian
  • Gomez, Laurent
  • Hudson, Andrew Richard
  • Marrone, Tami Jo
  • Peters, Marco
  • Vickers, Troy

Abstract

Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

IPC Classes  ?

  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

30.

Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones

      
Application Number 15394058
Grant Number 10105367
Status In Force
Filing Date 2016-12-29
First Publication Date 2017-06-29
Grant Date 2018-10-23
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Branstetter, Bryan
  • Breitenbucher, James
  • Dyck, Brian
  • Gomez, Laurent
  • Hudson, Andrew Richard
  • Marrone, Tami Jo
  • Peters, Marco
  • Vickers, Troy
  • Weinhouse, Michael

Abstract

Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

31.

Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors

      
Application Number 15306069
Grant Number 09932345
Status In Force
Filing Date 2015-04-22
First Publication Date 2017-03-02
Grant Date 2018-04-03
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Breitenbucher, James
  • Freestone, Graeme
  • Gomez, Laurent
  • Lemus, Robert
  • Ly, Kiev
  • Mccarrick, Margaret
  • Vernier, William
  • Vickers, Troy

Abstract

2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/22 - Anxiolytics
  • A61P 25/24 - Antidepressants
  • A61P 25/00 - Drugs for disorders of the nervous system

32.

Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors

      
Application Number 15306064
Grant Number 09708334
Status In Force
Filing Date 2015-04-22
First Publication Date 2017-02-16
Grant Date 2017-07-18
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Basinger, Jillian
  • Bookser, Brett
  • Chen, Mi
  • Chung, Demichael
  • Gupta, Varsha
  • Hudson, Andrew
  • Kaplan, Alan
  • Na, James
  • Renick, Joel
  • Santora, Vincent

Abstract

5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

33.

SYSTEMS AND METHODS FOR COGNITIVE TESTING

      
Application Number US2016031056
Publication Number 2016/179434
Status In Force
Filing Date 2016-05-05
Publication Date 2016-11-10
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Cheung, Philip
  • Mcneil, John, Austin
  • Elam, Mary, Elise
  • Hannan, Fabiha, Johura
  • Hausman-Cohen, Ari, Nesher
  • Huang, Xin
  • Krupa, Sebastian
  • Legrain, Guillaume, Christian Rene
  • Nguyen, Minh, Triet Truong
  • Principato, Marjorie, Rose
  • Rabasca, Maggie, Camille
  • Swafford, Alexander, Pierce Orive
  • Vickland, Zachary, Scott
  • Yang, Tiancheng

Abstract

Methods, systems, apparatuses, and devices for modular testing of animals are disclosed. In one aspect, a system includes a modular hardware controller, configured to include at least two modular interfaces, allowing interconnection of one or more child controller circuit boards. Each child controller circuit board may, via one or more sensors or devices, receive input from or provide output to a testing chamber of an animal testing enclosure. The child controller boards may collectively control an environment within the testing chamber and provide visual stimulus to an animal under test within the enclosure. One or more of the child controller boards may also receive input from one or more input devices positioned within the testing chamber, such as a touch screen of an electronic display.

IPC Classes  ?

  • G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
  • G09B 19/00 - Teaching not covered by other main groups of this subclass
  • A01K 1/03 - Housing for domestic or laboratory animals

34.

COGNITIVE TEST EXECUTION AND CONTROL

      
Application Number US2016031047
Publication Number 2016/179428
Status In Force
Filing Date 2016-05-05
Publication Date 2016-11-10
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Cheung, Philip
  • Mcneil, John, Austin
  • Elam, Mary, Elise
  • Hannan, Fabiha, Johura
  • Hausman-Cohen, Ari, Nesher
  • Huang, Xin
  • Krupa, Sebastian
  • Legrain, Guillaume, Christian Rene
  • Nguyen, Minh, Triet Truong
  • Principato, Marjorie, Rose
  • Rabasca, Maggie, Camille
  • Swafford, Alexander, Pierce Orive
  • Vickland, Zachary, Scott
  • Yang, Tiancheng

Abstract

Features are provided to dynamically configure a testing system, including those using a script-based domain specific language to represent test protocols. Additional features to execute the tests across test systems and collect results are also provided. Dynamic test control features are also described to adjust a specific test execution using feedback from the testing system, such as a hardware component included in the system, to ensure the test complies with the protocol. As one non-limiting advantage, the described features help reduce environmental and procedural variability to ensure the cognitive variable(s) under test are isolated and controlled locally to comply with the protocol.

IPC Classes  ?

  • G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
  • G09B 19/00 - Teaching not covered by other main groups of this subclass

35.

SYSTEMS AND METHODS FOR COGNITIVE TESTING

      
Application Number US2016031051
Publication Number 2016/179432
Status In Force
Filing Date 2016-05-05
Publication Date 2016-11-10
Owner DART NEUROSCIENCE, LLC (USA)
Inventor
  • Cheung, Philip
  • Mcneil, John Austin
  • Elam, Mary Elise
  • Hannan, Fabiha Johura
  • Hausman-Cohen, Ari Nesher
  • Huang, Xin
  • Krupa, Sebastian
  • Legrain, Guillaume Christian Rene
  • Nguyen, Minh Triet Truong
  • Principato, Marjorie Rose
  • Rabasca, Maggie Camille
  • Swafford, Alexander Pierce Orive
  • Vickland, Zachary Scott
  • Yang, Tiancheng

Abstract

Methods, systems, and networks for cognitive testing of an animal based on a modular controller system are disclosed. In one aspect, a central hub processor is configured to provide a testing command for a testing station that accommodates the animal and includes one or more independent, secondary (or child) controllers. In another aspect, a main controller is configured to receive and parse the testing commands from the central hub processor. In other aspects, the child controllers are configured to execute the testing commands, receive responses to the testing commands from the animal, and provide feedback regarding the responses.

IPC Classes  ?

  • G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
  • G09B 19/00 - Teaching not covered by other main groups of this subclass

36.

Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones

      
Application Number 14853856
Grant Number 09533996
Status In Force
Filing Date 2015-09-14
First Publication Date 2016-03-17
Grant Date 2017-01-03
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Branstetter, Bryan
  • Breitenbucher, James
  • Dyck, Brian
  • Gomez, Laurent
  • Hudson, Andrew Richard
  • Marrone, Tami Jo
  • Peters, Marco
  • Vickers, Troy
  • Weinhouse, Michael

Abstract

Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

IPC Classes  ?

  • C07D 495/14 - Ortho-condensed systems
  • C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
  • C07D 471/14 - Ortho-condensed systems
  • C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
  • C07D 487/14 - Ortho-condensed systems
  • C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
  • C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
  • C07D 498/08 - Bridged systems
  • C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 495/12 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

37.

Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds

      
Application Number 14408927
Grant Number 09499562
Status In Force
Filing Date 2013-06-18
First Publication Date 2016-02-04
Grant Date 2016-11-22
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Branstetter, Bryan
  • Breitenbucher, James
  • Dyck, Brian
  • Gomez, Laurent
  • Hudson, Andrew Richard
  • Marrone, Tami Jo
  • Peters, Marco
  • Vickers, Troy

Abstract

Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

IPC Classes  ?

  • C07D 495/14 - Ortho-condensed systems
  • C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
  • C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
  • C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
  • C07D 487/14 - Ortho-condensed systems
  • C07D 471/14 - Ortho-condensed systems
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D 498/08 - Bridged systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 495/12 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

38.

Therapeutic isoxazole compounds

      
Application Number 14709206
Grant Number 09650349
Status In Force
Filing Date 2015-05-11
First Publication Date 2015-11-26
Grant Date 2017-05-16
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Kaplan, Alan
  • Keenan, Terence
  • Mcriner, Andrew

Abstract

The invention provides a compound of formula I: 1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

IPC Classes  ?

  • A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 491/044 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

39.

Substituted pyridine and pyrazine compounds as PDE4 inhibitors

      
Application Number 14720321
Grant Number 09573937
Status In Force
Filing Date 2015-05-22
First Publication Date 2015-11-19
Grant Date 2017-02-21
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Bollu, Venkataiah
  • Breitenbucher, James
  • Kaplan, Alan
  • Lemus, Robert
  • Lindstrom, Andrew
  • Vickers, Troy
  • Wilson, Mark
  • Zapf, James

Abstract

The invention provides a chemical entity of Formula (I) 4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

IPC Classes  ?

  • C07D 241/18 - Oxygen or sulfur atoms
  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 213/64 - One oxygen atom attached in position 2 or 6
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 213/73 - Unsubstituted amino or imino radicals
  • C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
  • C07D 213/81 - AmidesImides
  • A61K 51/04 - Organic compounds
  • C07D 239/34 - One oxygen atom

40.

Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders

      
Application Number 14408942
Grant Number 09284335
Status In Force
Filing Date 2013-06-18
First Publication Date 2015-06-11
Grant Date 2016-03-15
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Allan, Amy
  • Branstetter, Bryan
  • Dyck, Brian
  • Gomez, Laurent
  • Marrone, Tami Jo
  • Peters, Marco
  • Weinhouse, Michael I.

Abstract

Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • C07D 239/70 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 495/14 - Ortho-condensed systems
  • C07D 498/08 - Bridged systems
  • C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
  • C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
  • C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
  • C07D 471/14 - Ortho-condensed systems
  • C07D 487/14 - Ortho-condensed systems
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

41.

Substituted pyridine and pyrazine compounds as PDE4 inhibitors

      
Application Number 14204934
Grant Number 09120770
Status In Force
Filing Date 2014-03-11
First Publication Date 2014-10-23
Grant Date 2015-09-01
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Bollu, Venkataiah
  • Breitenbucher, James
  • Kaplan, Alan
  • Lemus, Robert
  • Lindstrom, Andrew
  • Vickers, Troy
  • Wilson, Mark E.
  • Zapf, James

Abstract

The invention provides a chemical entity of Formula (I) 4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

IPC Classes  ?

  • C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 213/64 - One oxygen atom attached in position 2 or 6
  • C07D 241/18 - Oxygen or sulfur atoms
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

42.

Substituted pyridine and pyrazine compounds as PDE4 inhibitors

      
Application Number 14205033
Grant Number 09040692
Status In Force
Filing Date 2014-03-11
First Publication Date 2014-09-18
Grant Date 2015-05-26
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Bollu, Venkataiah
  • Breitenbucher, James
  • Kaplan, Alan
  • Lemus, Robert
  • Lindstrom, Andrew
  • Vickers, Troy
  • Wilson, Mark E.
  • Zapf, James

Abstract

The invention provides a chemical entity of Formula (I) 4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

IPC Classes  ?

  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 213/64 - One oxygen atom attached in position 2 or 6
  • C07D 241/18 - Oxygen or sulfur atoms
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

43.

Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones

      
Application Number 13920974
Grant Number 09175010
Status In Force
Filing Date 2013-06-18
First Publication Date 2013-12-19
Grant Date 2015-11-03
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Branstetter, Bryan
  • Breitenbucher, James
  • Dyck, Brian
  • Gomez, Laurent
  • Hudson, Andrew Richard
  • Marrone, Tami Jo
  • Peters, Marco
  • Vickers, Troy
  • Weinhouse, Michael I.

Abstract

Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

IPC Classes  ?

  • C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
  • C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
  • C07D 487/14 - Ortho-condensed systems
  • C07D 498/08 - Bridged systems
  • C07D 471/14 - Ortho-condensed systems
  • C07D 495/14 - Ortho-condensed systems
  • C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
  • C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

44.

Therapeutic isoxazole compounds

      
Application Number 13542358
Grant Number 09029397
Status In Force
Filing Date 2012-07-05
First Publication Date 2013-02-28
Grant Date 2015-05-12
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Kaplan, Alan P.
  • Keenan, Terence P.
  • Mcriner, Andrew J.

Abstract

The invention provides a compound of formula I: 1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

IPC Classes  ?

  • A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 491/044 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

45.

Therapeutic piperazines

      
Application Number 12861213
Grant Number 08338405
Status In Force
Filing Date 2010-08-23
First Publication Date 2011-03-17
Grant Date 2012-12-25
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Keenan, Terence P.
  • Kaplan, Alan P.

Abstract

The invention includes a compound of formula I: 1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in animals.

IPC Classes  ?

  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/4965 - Non-condensed pyrazines

46.

METHODS AND SYSTEMS FOR EVALUATING MEMORY AGENTS

      
Application Number US2009051082
Publication Number 2010/009453
Status In Force
Filing Date 2009-07-17
Publication Date 2010-01-21
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Tully, Timothy
  • Davachi, Lila

Abstract

The present invention provides methods and systems for identifying, evaluating, and testing various compounds as memory agents and regimens as training protocols related to memory enhancement and/or impairment. Such methods and systems may test any compounds or protocols, including the memory agents and training protocols described herein. The methods can comprise combining training protocols with the general administration of memory agents. In some embodiments, the present invention may involve identifying, selecting, testing, evaluating or assessing a compound as a drug candidate for a memory agent, for example, as one effective for enhancing or impairing memory.

IPC Classes  ?

  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

47.

Therapeutic isoxazole compounds

      
Application Number 12198686
Grant Number 08222243
Status In Force
Filing Date 2008-08-26
First Publication Date 2009-03-05
Grant Date 2012-07-17
Owner DART NEUROSCIENCE LLC (USA)
Inventor
  • Kaplan, Alan P.
  • Keenan, Terence P.
  • Mcriner, Andrew J.

Abstract

The invention provides a compound of formula I: 1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

IPC Classes  ?

  • A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
  • C07D 243/00 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 221/02 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups condensed with carbocyclic rings or ring systems
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 261/06 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members

48.

PEPTIDES FACILITATING RETROGRADE TRANSPORT AND THEIR USES

      
Application Number US2008069365
Publication Number 2009/006638
Status In Force
Filing Date 2008-07-07
Publication Date 2009-01-08
Owner DART NEUROSCIENCES, LLC (USA)
Inventor Bearer, Elaine, L.

Abstract

The present invention concerns peptides facilitating retrograde transport and their uses. In particular, the invention concerns the peptides of KlP VIE NPQ YFG ITN (SEQ ID NO: 1) and KRE LGE GAF GKV FLA (SEQ ID NO: 2).

IPC Classes  ?

  • C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
  • C07K 14/43 - Thaumatin
  • A61K 38/08 - Peptides having 5 to 11 amino acids
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material